Targeting the target of rapamycin (TOR): looking to mother nature.

作者: Eric K. Rowinsky

DOI: 10.1007/S11523-011-0180-Y

关键词:

摘要:

参考文章(34)
Arie Zask, Jeroen C Verheijen, David J Richard, Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Current Opinion in Drug Discovery & Development. ,vol. 13, pp. 428- 440 ,(2010)
Giuseppe Giaccone, Ariel Lopez-Chavez, Corey A. Carter, The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Current opinion in investigational drugs. ,vol. 10, pp. 1305- 1314 ,(2009)
Scott A. Soefje, Anand Karnad, Andrew J. Brenner, Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncology. ,vol. 6, pp. 125- 129 ,(2011) , 10.1007/S11523-011-0174-9
Sushma Vemulapalli, Alain Mita, Yesid Alvarado, Kamalesh Sankhala, Monica Mita, None, The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Targeted Oncology. ,vol. 6, pp. 29- 39 ,(2011) , 10.1007/S11523-011-0179-4
E-Hu Liu, Lian-Wen Qi, Qian Wu, Yong-Bo Peng, Ping Li, Anticancer agents derived from natural products. Mini-reviews in Medicinal Chemistry. ,vol. 9, pp. 1547- 1555 ,(2009) , 10.2174/138955709790361520
Tadeusz F. Molinski, Doralyn S. Dalisay, Sarah L. Lievens, Jonel P. Saludes, Drug development from marine natural products Nature Reviews Drug Discovery. ,vol. 8, pp. 69- 85 ,(2009) , 10.1038/NRD2487
Reuben J Shaw, Nabeel Bardeesy, Brendan D Manning, Lyle Lopez, Monica Kosmatka, Ronald A DePinho, Lewis C Cantley, The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell. ,vol. 6, pp. 91- 99 ,(2004) , 10.1016/J.CCR.2004.06.007
Ken Inoki, Tianqing Zhu, Kun-Liang Guan, TSC2 mediates cellular energy response to control cell growth and survival. Cell. ,vol. 115, pp. 577- 590 ,(2003) , 10.1016/S0092-8674(03)00929-2